Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Sosei Heptares

Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals
- Payment follows dosing of the first patient in a Phase 3 trial of APP13007 for the treatment of inflammation and pain after cataract surgery 
Tickers SOLTF
From PR Newswire
Sosei Heptares spin-off company Orexia Therapeutics merged into newly created Centessa Pharmaceuticals
- Centessa combines 10 privately held biotech companies with highly validated programs led by industry leading teams 
From PR Newswire
Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months ended 31 December 2020
Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2020. The full report can be... 
Tickers SOLTF
From PR Newswire
Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences
Ion channels represent a large but under-exploited class of drug targets beyond G protein-coupled proteins (GPCRs) 
Tickers SOLTF
From PR Newswire
Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-driven Drug Discovery against Challenging GPCR Target
- Collaboration combines Sosei Heptares' leading structure-based drug design platform with PharmEnable's advanced artificial intelligence-enabled and medicinal chemistry technologies 
Tickers SOLTF
From PR Newswire
Sosei Heptares to present at 39th Annual J.P. Morgan Healthcare Conference
Sosei Group Corporation ("the Company";) (TSE: 4565), today announced its Chief Financial Officer, Chris Cargill, will present at the 39th Annual J.P. Morgan Healthcare Conference, which will take... 
From PR Newswire
Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs
Sosei Group Corporation ("the Company") (TSE: 4565) announces it is to regain the worldwide rights to its muscarinic agonist programs. The program was licensed to Allergan in April 2016, and Allergan... 
Tickers SOLTF
From PR Newswire
Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
- Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders 
Tickers SOLTF
From PR Newswire
Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System
- Single-target agreement focused on small molecule agonists of GPR35, a genetically validated target for inflammatory bowel disease and other gastrointestinal immune disorders 
Tickers SOLTF
From PR Newswire
Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio
- Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists 
Tickers BHVN SOLTF
From PR Newswire
Sosei Heptares' COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development
- Program focused on inhibitors of SARS-CoV-2 main protease, a highly conserved protein essential for viral replication 
Tickers SOLTF
From PR Newswire
Sosei Heptares Operational Highlights and Consolidated Results for the Nine Months ended 30 September 2020
Sosei Group Corporation ("the Company"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the nine months ended 30 September 2020. The full report is... 
From PR Newswire
Sosei Heptares and Aditum Bio create new company - Tempero Bio - to advance the clinical development of mGlu5 NAM program in neurological diseases
- Aditum Bio, established by industry veterans Joe Jimenez and Mark Fishman, to fund clinical development 
From PR Newswire
Sosei Heptares announces that a second novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials
- Dosing of first subject in clinical trial by Pfizer triggers $5 million payment to Sosei Heptares 
Tickers SOLTF
From PR Newswire
Sosei Heptares Appoints Top-Ranked Investment Analyst Hironoshin Nomura as Senior Vice President, Investor Relations and Corporate Strategy
Sosei Group Corporation ("the Company") (TSE: 4565) today announces the appointment of Hironoshin Nomura, as Senior Vice President Investor Relations and Corporate Strategy. Mr. Nomura, who will lead... 
Tickers SOLTF
From PR Newswire
Sosei Heptares Operational Highlights and Consolidated Results for the First Half 2020
Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the first half ended 30 June 2020. The full report can be... 
Tickers SOLTF
From PR Newswire
Sosei Heptares Successfully Raises US$200 million in International Offering of New Shares and Convertible Bonds
Funds to be used to drive transformative strategic growth initiatives 
Tickers SOLTF
From PR Newswire
Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma
- Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily Tio in improving quality of life... 
Tickers SOLTF
From PR Newswire
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2020
Sosei Group Corporation ("the Company"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2020. The full report can be... 
Tickers SOLTF
From PR Newswire
Sosei Heptares Announces Further Scientific Progress with Orexin Agonist Program in Conjunction With Spin-off Companies Orexia and Inexia
- Sosei Heptares solves structure of the agonist bound orexin OX2 receptor and identifies small molecule binding site using unique StaR® technology and structure-based approach 
Tickers SOLTF
From PR Newswire
Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma
- Positive opinion received from European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) 
Tickers SOLTF
From PR Newswire
Sosei Heptares to Apply its Structure-based Drug Design Expertise in New COVID-19 R&D Program
- New program to focus initially on inhibitors of SARS-CoV-2 protease, a protein essential for the viral life cycle 
Tickers SOLTF
From PR Newswire
Sosei Heptares Announces New Board Director Appointment and Executive Promotion
- Strengthened focus on the execution of the next stage of growth strategy 
Tickers SOLTF
From PR Newswire
Sosei Heptares Announces New Publication Highlighting the Potential of Structure-based Approaches to Generate Novel Peptide-based Drugs Targeting GPCRs
- Published in leading peer-reviewed journal Nature Reviews Drug Discovery 
Tickers SOLTF
From PR Newswire
Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months Ended 31 December 2019
Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the twelve months ended 31 December 2019. The full report can... 
Tickers SOLTF
From PR Newswire
Sosei Heptares: Significant Progress by Orexia and Inexia With Orexin Agonist Program Triggers Next Tranche of Funding From Medicxi
- Orexin program targeting neurological diseases being developed through spin-off companies Orexia and Inexia and financed with €40 million investment from Medicxi 
Tickers SOLTF
From PR Newswire
Sosei Heptares Announces Nomination of a Third Clinical Candidate by Pfizer from Multi-target Drug Discovery Collaboration
- Nomination of new clinical candidate triggers $3 million payment to Sosei Heptares 
From PR Newswire
Sosei Heptares Announces the First Phase I Clinical Start From Its Multi-target Drug Discovery Collaboration With Pfizer
- Dosing of first subject in clinical trial by Pfizer triggers $5 million payment to Sosei Heptares 
Tickers SOLTF
From PR Newswire
Sosei Heptares Announces That the COPD Treatment Ultibro® Breezhaler® has been Included in the National Reimbursement Drug List in China
Inclusion in NRDL supports improved access to novel treatments for eligible patients 
Tickers SOLTF
From PR Newswire
Sosei Heptares Creates New World-Class International Scientific Advisory Board to Support Strategic Decision-Making Aligned with Corporate Objectives
Sosei Group Corporation ("the Company"; TSE: 4565) announces the formation of a new Scientific Advisory Board (SAB) to advise on the Company's scientific strategy in support of its corporate... 
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account